Congress Asset Management Co. Boosts Stock Position in Medpace Holdings, Inc. $MEDP

Key Points

• Congress Asset Management Co. has increased its stake in Medpace Holdings, Inc. by 4.6%, owning 57,505 shares worth approximately $18 million as of the second quarter.
• Insider sales have been notable, with CFO Kevin M. Brady and VP Susan E. Burwig selling significant shares, resulting in a 66.67% and 14.81% decrease in their respective holdings.
• Medpace reported strong quarterly earnings, with an EPS of $3.10, beating analyst estimates, and has set a fiscal year 2025 guidance of 13.760-14.53 EPS.

Congress Asset Management Co. boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 4.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,505 shares of the company's stock after acquiring an additional 2,517 shares during the quarter. Congress Asset Management Co. owned 0.20% of Medpace worth $18,049,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MEDP. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Brooklyn Investment Group increased its stake in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after buying an additional 71 shares during the period. Whittier Trust Co. raised its stake in shares of Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after acquiring an additional 35 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Medpace in the 1st quarter valued at about $60,000. Finally, Assetmark Inc. raised its holdings in Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after acquiring an additional 43 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Medpace

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of the stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares of the company's stock, valued at approximately $2,725,380. This trade represents a 66.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 10,000 shares of Medpace stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total value of $4,800,000.00. Following the completion of the transaction, the vice president owned 57,500 shares in the company, valued at $27,600,000. This trade represents a 14.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 161,266 shares of company stock valued at $74,111,427. Corporate insiders own 20.30% of the company's stock.

Medpace Trading Up 1.8%

Shares of MEDP opened at $496.79 on Friday. The firm has a market cap of $13.95 billion, a PE ratio of 36.94, a price-to-earnings-growth ratio of 3.07 and a beta of 1.44. The company's 50 day simple moving average is $464.83 and its 200-day simple moving average is $360.76. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $506.55.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. During the same quarter in the prior year, the firm earned $2.75 EPS. Medpace's revenue for the quarter was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MEDP. Cowen downgraded Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Jefferies Financial Group increased their price target on shares of Medpace from $400.00 to $450.00 and gave the company a "hold" rating in a research note on Tuesday, September 9th. Rothschild Redb cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 3rd. UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and upped their target price for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Finally, William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Reduce" and an average price target of $422.27.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.